Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 2
1992 2
1993 3
1994 4
1995 5
1996 18
1997 23
1998 43
1999 30
2000 38
2001 33
2002 35
2003 42
2004 46
2005 32
2006 35
2007 40
2008 46
2009 41
2010 33
2011 25
2012 31
2013 41
2014 29
2015 30
2016 31
2017 24
2018 28
2019 25
2020 28
2021 26
2022 14
2023 17
2024 28
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

866 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of dorzolamide.
Martens-Lobenhoffer J, Banditt P. Martens-Lobenhoffer J, et al. Clin Pharmacokinet. 2002;41(3):197-205. doi: 10.2165/00003088-200241030-00004. Clin Pharmacokinet. 2002. PMID: 11929320 Review.
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower th
Nephrolithiasis with dorzolamide.
Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Carlsen J, et al. Arch Ophthalmol. 1999 Aug;117(8):1087-8. doi: 10.1001/archopht.117.8.1087. Arch Ophthalmol. 1999. PMID: 10448757 No abstract available.
Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future.
Konstas AG, Schmetterer L, Katsanos A, Hutnik CML, Holló G, Quaranta L, Teus MA, Uusitalo H, Pfeiffer N, Katz LJ. Konstas AG, et al. Adv Ther. 2021 Jan;38(1):24-51. doi: 10.1007/s12325-020-01525-5. Epub 2020 Oct 27. Adv Ther. 2021. PMID: 33108623 Free PMC article. Review.
The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence and clinical experience. ...The pharmacological properties of DTFC reflect those of its two …
The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free …
Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
Ormrod D, McClellan K. Ormrod D, et al. Drugs Aging. 2000 Dec;17(6):477-96. doi: 10.2165/00002512-200017060-00005. Drugs Aging. 2000. PMID: 11200308 Review.
The nonselective beta-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol and dorzolamide have different mechanisms of action and their effects are additive when administered together. ...Clinical trials in …
The nonselective beta-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol …
Dorzolamide intermediates with potential anti-inflammatory activity.
Atre R, Obukhov AG, Majmudar CY, Nair K, White FA, Sharma R, Siddiqi F, Faisal SM, Varma VP, Hassan MI, Mohammad T, Darwhekar GN, Baig MS. Atre R, et al. Eur J Pharmacol. 2025 Jan 15;987:177160. doi: 10.1016/j.ejphar.2024.177160. Epub 2024 Dec 2. Eur J Pharmacol. 2025. PMID: 39631651
Dorzolamide (DZD), a Carbonic anhydrase (CA) inhibitor clinically used to lower intraocular pressure, exhibits anti-inflammatory effects owing to the drug's ability to inhibit the TIR domain-containing adaptor protein (TIRAP)-mediated signalling in macrophages. ...
Dorzolamide (DZD), a Carbonic anhydrase (CA) inhibitor clinically used to lower intraocular pressure, exhibits anti-inflammatory effe
Latanoprost versus combined timolol and dorzolamide.
Bron AM, Emmerich KH. Bron AM, et al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S148-54. doi: 10.1016/s0039-6257(02)00290-4. Surv Ophthalmol. 2002. PMID: 12204712 Review.
We conclude that the effect on IOP reduction of latanoprost is similar to combined timolol and dorzolamide, and the additive effect of latanoprost to a combination of timolol and dorzolamide is clinically relevant. In most cases, the overall safety profile of latano …
We conclude that the effect on IOP reduction of latanoprost is similar to combined timolol and dorzolamide, and the additive effect o …
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive t …
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and …
Topical drug delivery to the eye: dorzolamide.
Loftsson T, Jansook P, Stefánsson E. Loftsson T, et al. Acta Ophthalmol. 2012 Nov;90(7):603-8. doi: 10.1111/j.1755-3768.2011.02299.x. Epub 2012 Jan 23. Acta Ophthalmol. 2012. PMID: 22269010 Free article. Review.
The solid dorzolamide/gammaCD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended time period. Consequently, sustained high dorzolamide concentrations in aqueous humour and various eye tissues were observed after s …
The solid dorzolamide/gammaCD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended …
Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
Balfour JA, Wilde MI. Balfour JA, et al. Drugs Aging. 1997 May;10(5):384-403. doi: 10.2165/00002512-199710050-00006. Drugs Aging. 1997. PMID: 9143858 Review.
Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical use, lowers intraocular pressure (IOP) by reducing aqueous humour formation. ...The most common adverse effects associated with dorzolami
Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical
Allergic contact dermatitis due to dorzolamide eyedrops.
Mitsuyama S, Abe F, Higuchi T. Mitsuyama S, et al. Contact Dermatitis. 2021 Jan;84(1):58-59. doi: 10.1111/cod.13671. Epub 2020 Aug 24. Contact Dermatitis. 2021. PMID: 32700819 No abstract available.
866 results